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To document anxiety and depression from pretreatment till 5-year follow-up in 299 men with localized prostate cancer. To assess, if
baseline scores were predictive for anxiety and depression at 1-year follow-up. Respondents completed four assessments
(pretreatment, at 6 and 12 months, and at 5-year follow-up) on anxiety, depression and mental health. Respondents were subdivided
according to therapy (prostatectomy or radiotherapy) and high vs low-anxiety. Pretreatment 28% of all patients were classified as
‘high-anxiety’; their average anxiety scores decreased significantly post-treatment, that is towards less anxiety. At all assessments, high-
anxiety men treated by prostatectomy reported less depression than high-anxiety men treated by radiotherapy. Of men treated by
radiotherapy, 27% reported clinical significant levels of depression while 20% is expected in a general population. The improvement in
mental health at 6-months follow-up was statistically significant and clinically meaningful in all respondent groups. Sensitivity of anxiety
at baseline as a screening tool was 71% for anxiety and 60% for symptoms of depression. We recommend clinicians to attempt early
detection of patients at risk of high levels of anxiety and depression after prostate cancer diagnosis since prevalence is high. STAI-
State can be a useful screening tool but needs further development.
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Prostate cancer is highly prevalent in most Western countries
(Parkin et al, 2001). Prostate cancer can be detected early by PSA-
testing, a biologic tumour marker. Radical prostatectomy and
external beam radiotherapy are the most commonly used
intentionally curative primary therapies.
Being diagnosed with prostate cancer leads to anxiety, but not to
the same extent in every patient (Balderson and Towell, 2003;
Carlson et al, 2004; Steginga et al, 2004). In a recent study, some
30% of the participating prostate cancer patients met criteria for
general distress in the clinical range (Carlson et al, 2004). In a
retrospective, cross-sectional study among men with prostate
cancer who were seeking psychological support, the prevalence of
severe psychological distress was 37% (35/94) (Balderson and
Towell, 2003). Although several longitudinal studies with a follow-
up longer than 12 months have reported on mental health or
emotional well-being after prostate cancer treatment (Potosky
et al, 2000; Galbraith et al, 2001; Litwin et al, 2001, 2002; Korfage
et al, 2005), the long-term impact of prostate cancer diagnosis and
treatment on anxiety and feelings of depression in men is not
known.
The high prevalence of severe distress after prostate cancer
diagnosis has resulted in the recommendation to target interven-
tions at treatment decision-related distress for all men and to offer
in-depth psychological support for those who experience ongoing
difficulties (Steginga et al, 2004). Yet, for clinicians and patients it
would be useful if individual patients at risk of prolonged
psychological distress could be identified shortly after diagnosis.
To identify high-anxiety men who might need psychological
support several instruments have been developed, for example the
Memorial Anxiety Scale for Prostate Cancer (MAX-PC) (Roth et al,
2003) or the Hospital Anxiety and Depression Scale (HADS)
(Nordin et al, 2001). Results were promising, but follow-up
relatively short (2 weeks–6 months). We conducted a prospective
study with 5-year follow-up in newly diagnosed prostate cancer
patients to (1) document the course of anxiety and depression
from before the initiation of treatment; and (2) evaluate the
predictive accuracy of baseline scores at the individual level for
anxiety and depression in the year following diagnosis.
PATIENTS AND METHODS
Ethics approval and informed consent
The ethics review committee of the Erasmus MC, the University
Medical Center Rotterdam, the Netherlands, approved of the
research protocol. All participating men gave written informed
consent.
Patients and procedures
All consecutive newly diagnosed prostate cancer patients from four
Rotterdam hospitals were recruited between June 1996 and January
1999. Respondents were diagnosed through the ERSPC screening
trial or in a clinical setting. Exclusion criteria were (1) referral to
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swatchful waiting or advanced disease therapy; (2) noncompletion
of the STAI-State scores (see below), since this score was crucial in
assessing the respondents’ anxiety level at baseline. The prospec-
tive study consisted of four measurements: 1 month before
initiation of primary therapy, and at 6 months, 12 months and
5-year follow-up. The nonrandomly allocated treatment consisted
of (intentionally nerve-sparing) radical prostatectomy or external
beam radiotherapy (comprising an average of 33 radiation sessions
over 7 weeks). Further details on the study design and the
inclusion of respondents were published previously (Korfage et al,
2005).
Patients’ characteristics
Information on age, marital status, education, comorbidity and
profession was obtained from the respondents. Educational level
was classified as low (primary school or lower technical educa-
tion), intermediate or high (college/university degree). To assess
the prevalence of comorbidity, we used a standardized list of 28
chronic conditions, such as heart failure, asthma, diabetes and
asked respondents to report which condition they currently
experienced or had experienced during the previous year (Dutch
Health Interview Survey, Statistics Netherlands).
Baseline clinical information on tumour stage (Hermanek and
Sobin, 1992), histopathologic tumour (biopsy) grade and urologic
treatment history were obtained from the Regional Cancer
Registry. Possible postoperative adjustments to staging in the
prostatectomy group were not included to maintain comparability
with the radiotherapy group. Data on the clinical or biochemical
progression at the 5-year assessment were obtained from the
treating physicians. Biochemical recurrence was defined as a PSA-
level of at least 0.2ngml
 1 after prostatectomy, confirmed at least
once, or as a rise in PSA-level of at least 0.5ngml
 1 after
radiotherapy, confirmed at least once.
Psychological measures
The questionnaires contained three validated self-report psycho-
logical measures.
Anxiety was assessed by the State Trait Anxiety Inventory
(STAI-State). This scale contains 20 items on, for instance, feeling
at ease or upset (Sesti, 2000). Scale scores range from 20 to 80 with
higher scores indicating higher levels of anxiety (van der Ploeg
et al, 1980). A STAI-State score of more than 44 defines an
individual as highly anxious (Spielberger and Vagg, 1984; Millar
et al, 1995). Applying this cutoff level, we defined men with
pretreatment STAI-State scores equal to or below 44 as ‘low-
anxiety’ and those with scores above 44 as ‘high-anxiety’.
The Center for Epidemiologic Studies Depression Scale (CES-D)
was used to assess the frequency and severity of symptoms of
depression. We applied the 20-item version with items relating to,
for instance, feeling depressed or fearful, being happy, and
enjoying life. Scores range from 0 to 60 with higher scores
indicating higher levels of symptoms of depression (Radloff, 1977).
A score of 16 or higher suggests a clinically significant level of
symptoms of depression, which does not necessarily mean that the
participant has a clinical diagnosis of depression. In a general
population sample, 20% of the participants had a CES-D score
above 16 (Bouma et al, 1995).
The Mental Health scale of the RAND 36-item Short-Form
Health Survey (SF36-MH) was used as a general measure of mental
health. The scale consists of five items on being nervous, down,
peaceful, depressed and happy. Item scores are transformed to
ranges of 0–100 with higher scores indicating better mental health
(Ware et al, 1993). Differences of at least 7.9 points are considered
clinically meaningful (Norman et al, 2001).
Procedures concerning imputation of missing items were
conducted according to the respective guidelines. STAI-State,
CES-D and SF36-MH scores are moderately to strongly correlated
ranging at baseline from 0.71 between STAI-State and CES-D to
0.83 between STAI-State and SF36-MH.
Statistical analysis
Respondents were subdivided into four groups, defined by therapy
(surgery or external radiotherapy) and by level of anxiety (high vs
low). Between-group and within-group differences in background
characteristics and descriptive statistics were calculated using SPSS
for Windows, release 10.0.7. The w
2 test was used for categorical
variables, the t-test or Mann–Whitney U for continuous variables.
P-values o0.05 (referring to two-sided statistical tests) were
considered significant.
The course of STAI-State, CES-D and SF36-MH scores within
therapy groups was analysed by repeated-measures analysis of
variance (ANOVA) using proc mixed from the SAS system for
Windows release 8.2. Random intercept models were applied that
allowed for the use of all available data, including incomplete
records. These models comprised the main effects of ‘anxiety’ and
‘time’ and the interaction between anxiety and time. Time was
included as a factor with four levels – one for each assessment - to
account for possible nonlinearities in the course of scale scores.
Comorbidity and PSA-level were included in the models as
covariates.
To compare the course of anxiety and symptoms of depression
in subgroups stratified by baseline anxiety scores, we calculated
mean scores at 6 and 12-months follow-up for respondents with
low (p44) and high (444) anxiety scores at baseline. To evaluate
the diagnostic performance of baseline anxiety screening, we
calculated the sensitivity, specificity, positive (PPV) and negative
predictive value (NPV) using data of all patients who completed
the first three assessments. This complete case analysis is a valid
strategy, because missing values at 1-year follow-up were not
related to levels of anxiety or symptoms of depression at baseline
nor to age.
Age
Average age differed considerably between treatment groups (76
years). Age-adjustment was not appropriate, because the relation
between age and the physical functions in particular was found to
be nonlinear (as the decline with ageing was generally steeper for
older subjects than for younger ones). Therefore, the average age
per treatment group is presented on the x-axes in our graphs –
analogous to earlier reported disease-specific and generic quality
of life scores of the same cohort (Korfage et al, 2005).
RESULTS
Patient’s characteristics
Between June 1996 and January 1999, 415 men met the inclusion
criteria, of whom 387 consented to participate and completed the
first questionnaire (93%). Men who were referred to watchful
waiting (n¼25) or advanced disease therapy (n¼48), or had not
completed the STAI-State at the first assessment (n¼15) were
excluded. The final cohort consisted of 299 primary prostate
cancer patients treated with radical prostatectomy (n¼118) or
external radiotherapy (n¼181). The response rate to all four
questionnaires was 78% (214 out of 275 men still alive at the 52-
month assessment). Median time to long-term follow-up was 52
months, and mean time 51 months (range: 44–56 months).
Table 1 reports patients’ characteristics per treatment group.
The table shows that the groups differed significantly in age, the
number of comorbid conditions, and the PSA-level before
treatment. On the basis of the STAI-State scores at the first
assessment, 25% of the prostatectomy (n¼29) and 30% of the
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sradiotherapy group (n¼55) were classified as high-anxiety.
Characteristics did not differ significantly between high-anxiety
and low-anxiety individuals within the two treatment groups,
except that in the radiotherapy group the percentage of singles was
higher among high-anxiety men compared to low-anxiety men
(26% vs 8%, P¼0.003).
Information on clinical or biochemical recurrence at the 5-year
assessment was available for 94% of the 5-year respondents;
prostate cancer had recurred in 5% (5/91) of the prostatectomy
patients and in 21% (26/123) of the radiotherapy patients.
Psychological measures
Scores of men treated by surgery were more favourable than those
treated by radiotherapy for all three psychological measures and at
all four assessments, that is, less anxiety and feelings of depression
and better mental health.
Pretreatment, 28% of all patients reported clinical levels of
anxiety (STAI-State 444), that is, 25% of the surgery group and
30% of the radiotherapy group. Average STAI-State scores in high-
anxiety men of 52 (surgery group) and 54 (radiotherapy group)
decreased significantly after treatment, that is, less anxiety, and
remained at the lower level through follow-up (Table 2). At all
assessments, surgically treated high-anxiety men reported less
anxiety than high-anxiety men treated by radiotherapy. Repeated
measures analysis showed a significantly different score pattern
within treatment groups (Po0.0001): although high-anxiety men
improved substantially at 6-months follow-up, they still reported
more anxiety than low-anxiety men (Figure 1A).
Compared to pretreatment, all groups except the high-anxiety
men treated by radiotherapy reported significantly lower CES-D
scores at 6-months follow-up, that is, less symptoms of depression
(Table 2). At all assessments, high-anxiety men treated by
prostatectomy reported less feelings of depression than high-
anxiety men after radiotherapy (Table 2). Repeated measures
analysis showed that although levels of feelings of depression
differed between high- and low-anxiety men, score patterns within
treatment groups did not statistically differ (Figure 1B).
At all assessments lower percentages of prostatectomy men
reported clinically significant levels of symptoms of depression
than the general population (9–18% vs 20%), pretreatment and at
5-year assessments in the radiotherapy group these percentages
were higher than 20% (27 and 22%).
Compared to pretreatment, the improvement in post-treatment
SF36-MH was not only statistically significant, but also clinically
meaningful (Ware et al, 1993) in all four respondent groups, see
Table 2. High-anxiety prostatectomy men reported better mental
health than high-anxiety radiotherapy men (Table 2). Repeated
measures analysis showed that although levels of SF36-MH differed
between high- and low-anxiety men, score patterns within
Table 1 Patient characteristics at baseline
Prostatectomy
(n¼118)
Radiotherapy
(n¼181) P-value
Age in years o0.001
Average (s.d. range) 62.6 (5.3, 50–75) 68.1 (5.8, 50–82)
Educational level (%) 0.10
Low 28% (31) 38% (66)
Intermediate 57% (62) 54% (94)
High 15% (16) 8% (14)
Marital status (%) 1
Married or cohabiting 87% (103) 87% (155)
Divorced or single 13% (15) 13% (24)
Comorbidity o0.001
Average number of conditions 0.7 1.2
PSA-level before treatment
(ngml
 1)
0.002
Average (s.d.) 9.7 (16.3) 15.7 (24.7)
Tumour stage before treatment 0.06
T1 18% (19) 12% (20)
T2 67% (71) 61% (103)
T3 15% (16) 27% (45)
T4 - 1% (2)
Tumour grade before treatment 0.78
G1 51% (54) 50% (86)
G2 38% (40) 37% (63)
G3 11% (11) 13% (23)
Table 2 Mean STAI-State, CES-D and SF36-MH by treatment and baseline anxiety level and standard deviation
Prostatectomy
a Radiotherapy
a
High-anxiety (n¼29) Low-anxiety (n¼89) All (n¼118) High-anxiety (n¼55) Low-anxiety (n¼126) All (n¼181)
Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
STAI-State (80–20)
Pretreatment 51.9 (7.8) 32.8 (7.5) 37.5 (11.2) 54.1 (7.7) 32.8 (6.5) 39.1 (11.7)
6 months 39.2
b (12.5) 29.8
b (8.4) 32.2
b (10.3) 45.6
b (11.8) 30.6
b (8.4) 34.9
b (11.5)
12 months 39.1 (11.6) 30.0 (8.7) 32.3 (10.2) 42.9 (11.4) 30.6 (9.7) 34.2 (11.6)
5 year 40.2 (11.3) 30.5 (8.4) 32.8 (10.1) 43.0 (10.3) 31.6
b (9.0) 34.4
b (10.5)
CES-D (60–0)
Pretreatment 16.8 (9.0) 7.6 (5.9) 9.9 (7.8) 19.9 (8.7) 8.1 (5.8) 11.2 (7.9)
6 months 13.0
b (12.3) 5.9
b (7.1) 7.7
b (9.1) 17.3 (11.0) 6.5
b (6.1) 9.4
b (8.9)
12 months 11.6 (9.8) 5.9 (6.8) 7.4 (10.0) 15.0 (10.1) 6.5 (6.6) 8.9 (8.7)
5 year 10.8 (9.7) 6.1 (5.7) 7.3 (7.0) 15.5 (8.7) 7.5
b (7.2) 9.6
b (8.4)
SF36-MH (0-100)
Pretreatment 55.4(13.3) 78.2 (11.5) 72.6 (15.5) 48.8 (14.3) 77.0 (11.2) 68.8 (17.2)
6 months 69.6
b (24.7) 86.0
b (13.9) 82.1
b (18.3) 64.7
b (22.3) 86.6
b (13.3) 80.3
b (18.9)
12 months 70.4 (21.3) 85.7 (14.2) 81.9 (17.4) 65.1 (20.8) 84.8 (15.4) 78.9 (19.4)
5 year 71.2 (19.5) 85.1 (12.9) 81.8 (15.7) 65.1 (21.9) 84.5 (15.7) 79.7 (19.2)
aDifferences between anxious and nonanxious groups were o0.001 for all scale scores and at all assessments.
bStatistically different (Po0.05) from previous assessment.
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streatment groups were not significantly different between the
groups (Figure 1C).
Predictive value of baseline scores
Table 3 shows the results of using the STAI-State score at baseline
as a screening tool to predict high levels of anxiety and feelings of
depression at the 6 and 12-months follow-up. The tool detected
71% of the patients who reported high anxiety at 6-months follow-
up (sensitivity¼71%), and 60% of those reporting a clinical level
of symptoms of depression (sensitivity¼60%). The probability of
a high-anxiety score at 6 or 12-months follow-up was 42% in
patients with a high-anxiety score at baseline (PPV¼42%), and
8% in those with low-anxiety scores (NPV¼92%). The probabi-
lities of high levels of symptoms of depression at follow-up were
38% (PPV¼38%) and 9% (NPV¼91%) in these groups.
DISCUSSION
We performed a prospective, longitudinal study on mental health
in 299 prostate cancer patients, using validated instruments. At
1 month before treatment roughly one in every four patients was
classified as ‘high-anxiety’. After 6 months, after initiation of
treatment, men reported significantly less anxiety and feelings of
depression and a significantly better mental health. Average scale
scores remained at the improved levels through follow-up.
Before interpreting the results from a clinical perspective, two
methodological issues have to be discussed. First, there is no
unequivocal cutoff value for the STAI to define high-anxiety. We
used the earlier reported cutoff value of 45 and higher (Millar et al,
1995; Roth et al, 1998) which matches almost perfectly with the
validated cutoff value of the HADS (Millar et al, 1995). Second,
nonresponse at 5-year follow-up was present. Although, repeated
measures analyses can take incomplete cases into account, we
excluded the 5-year assessment in evaluating the STAI-State as a
screening tool; because the nonresponse at 5-year follow-up was
significantly lower in high-anxiety men, a complete case analysis
would not be appropriate. Furthermore, it can be argued that a
prediction of high-anxiety at 12-months follow-up is clinically
more relevant, because high levels of anxiety or symptoms of
depression at 5-year follow-up may be unrelated to the preceding
prostate cancer diagnosis and treatment.
When we selected an anxiety measure around 1996, validated
Dutch versions of both STAI and HADS were available. We needed
only one measure and chose STAI, but, in retrospect, we could
have chosen HADS as well. We think that in this context there are
no really strong scientific arguments to prefer the one to the other.
Both are well-validated and commonly used measures for generic
anxiety, each with their own strengths and weaknesses. The
average STAI-State scores at baseline in the high-anxiety groups,
that is, 52 for surgery patients and 54 for radiotherapy, are high in
comparison to, for example, the mean STAI-State score in a group
of males with anxiety neurosis of 45 (van der Ploeg et al, 1980). Of
high-anxiety men, prostatectomy patients reported less anxiety
and feelings of depression and better mental health at follow-up
than radiotherapy patients. A first possible explanation is that the
level of anxiety influenced the treatment decision; high-anxiety
men may have perceived surgery as too frightening and therefore
opted for radiotherapy. A second explanation could be that surgery
led to more reassurance since – contrary to radiotherapy – the
prostate actually is removed. Previous research has suggested that
men may choose surgery on the basis of the lay belief that surgical
removal is the most effective way to cure cancer (Steginga et al,
2002). A third explanation could be age, since high-anxiety
radiotherapy men were significantly older than high-anxiety
prostatectomy men. However, for a number of reasons, age does
not seem to be the explanation. For instance, in spite of the
difference in average age low-anxiety men who were treated by
radiotherapy reported similar levels of anxiety and symptoms of
depression as surgically treated low-anxiety men. Furthermore,
several studies reported an association of higher age and lower
levels of anxiety. A review study, for instance, reported some
evidence that ageing is associated with an intrinsic reduction in
susceptibility to anxiety and depression (Jorm, 2000). Further-
more, older men reported better mental health, although higher
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Figure 1 (A) STAI-State scores during 5-year follow-up by treatment
group and baseline anxiety level. (B) CES-D scores during 5-year follow-up
by treatment group and baseline anxiety level. (C) SF-36 Mental Health
scores during 5-year follow-up by treatment group and baseline anxiety
level.
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sages were associated with worse physical health (Litwin et al,
2002). And finally, higher levels of anxiety were found in prostate
cancer patients younger than 65 years of age (Lintz et al, 2003). A
fourth possible explanation could be that compared to the high-
anxiety surgery group, a higher percentage of men were ‘single’ –
that is, in most cases divorced or widowed – in the high-anxiety
radiotherapy group. It has been reported before that marital status
contributes to happiness (Joung et al, 1994). A fifth possible
explanation could be the higher rate of recurrence in men treated
by radiotherapy vs men treated by surgery, that is, 21 vs 5%.
Within the radiotherapy group, the recurrence rate did not differ
significantly between high- and low-anxiety men.
The frequency of side effects in this same group of patients has
been reported elsewhere (Korfage et al, 2005). Four to five years
post-treatment, side effects were reported by higher percentages of
men treated by surgery than by men treated by radiotherapy, for
example, 88% of erectile dysfunction vs 64%, and 31% of urinary
leakage vs 13%. Thus side effects appear not to be the reason for
higher anxiety levels in men treated by radiotherapy.
Our findings are in line with a cohort study on 111 prostate
cancer patients with 12 months follow-up. Steginga et al (2004)
found that psychological and treatment decision-related distress
decreased with time, independent of treatment choice. At 12
months follow-up, most men experienced low levels of distress.
The authors suggested that, in general, men are resilient to the
experience of localized prostate cancer and adjust well psycholo-
gically. We agree that the majority of localized prostate cancer
patients seem to do fine in the 1–5 years following treatment, but
this is not the case for all patients. The challenge for clinicians is to
detect those men early who will experience ongoing clinical levels
of anxiety and symptoms of depression, and provide those with
in-depth support. A (short) anxiety measure could be a useful tool.
We applied a 20-item version of the STAI-State. Currently
validated 6-item versions are available in English (Marteau et al,
2001) and other languages such as Dutch (van der Bij et al, 2003).
Vedana and co-workers compared the Hospital anxiety and
depression scale (HADS) and STAI to identify the most suitable
instrument for screening a population at in-hospital intensive
rehabilitation on anxiety and depression. The sensitivity of the
STAI (52%) was less than that of the HADS (72%), but its
specificity (99%) was greater than that of HADS (84%). The
authors concluded that both instruments can be recommended
for psychological screening of patients in an in-hospital intensive
rehabilitation (Vedana et al, 2002). A cross-sectional study on
psychiatric disorders after successful renal transplantation as-
sessed the value of self-report scales, among others STAI and
HADS, in predicting anxiety and depression. HADS was found to
significantly (P¼0.003) predict anxiety and depression (Arapaslan
et al, 2004).
In our study, using the STAI-State baseline score as a screening
tool resulted in the early detection of 71, respectively, 60% of
patients who were to experience high levels of symptoms of
anxiety, respectively, feelings of depression at 6 or 12-months
follow-up. The sensitivity might be improved by expanding the
tool with, for instance, disease characteristics as the Gleason score,
or by applying other measures, for instance the HADS (Zigmond
and Snaith, 1983).
Treating clinicians may not always realize that, in spite of a
comparably favourable prognosis, so many patients experience
high levels of anxiety and symptoms of depression after a
diagnosis of localized prostate cancer. We recommend clinicians
to attempt early detection of patients at risk of such high levels and
provide them with psychological support. STAI-State can be a
useful screening tool but needs further development.
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